Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf334 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Noor Wortelboer und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Quality of Life, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Netherlands Organization for Health Research and Development, ZonMw, Zorgverzekeraars Nederland.
Abstract (Originalsprache)
Background
The SONIA trial demonstrated that addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after 2 treatment lines compared with addition to second-line (fulvestrant), while first-line use increased toxicity (74% more grade ≥3 adverse events) and costs. Understanding the impact of both treatment strategies on health-related quality of life (HRQOL) is critical to inform patient-centered treatment decisions.
Methods
HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL 5-dimensions 5-level questionnaires at up to 11 time points over the course of both treatment lines (follow-up) until SONIA treatment discontinuation. FACT-B total and subscale scores—including physical, social, emotional, functional well-being, and the breast cancer subscale—along with EuroQoL 5-dimensions 5-level scores were compared between treatment strategies using mixed linear regression models. Clinically meaningful differences were predefined as 7 points for the FACT-B total score and 2 points for subscales.
Results
Questionnaire completion rates for FACT-B were 88% at baseline and 75% during follow-up. No clinically or statistically significant differences in HRQOL were observed between treatment arms during follow-up. The estimated mean difference in FACT-B total score (CDK4/6i in second-line as reference) was −0.66 (95% confidence interval [CI] = −2.14 to 0.82; P = .39). Differences for subscales were similarly small.
Conclusion
HRQOL was comparable between patients receiving CDK4/6i in first- vs second-line across all measures, despite differences in toxicity rates. Clinical Trial Registration ClinicalTrials.gov (NCT03425838; https://www.clinicaltrials.gov/study/nct03425838).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Clinical Research Department, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
- Dutch Breast Cancer Society, Utrecht, the Netherlands.
ORCID-Profile: Noor Wortelboer, Hedwig M Blommestein, Annemiek van Ommen-Nijhof, Vincent van der Noort, Esther van den Pol, Aart Beeker, Joan B Heijns, Aafke H Honkoop, Paul C de Jong, A Elise van Leeuwen-Stok, Gabe S Sonke, Agnes Jager, Inge R Konings
Förderung
- Netherlands Organization for Health Research and Development
- ZonMw
- Zorgverzekeraars Nederland
- AstraZeneca
- Novartis
Zitieren
APA
Wortelboer, N., Kent, S., Blommestein, H. M., van Ommen-Nijhof, A., van der Noort, V., van den Pol, E., Páez, C. G., Beeker, A., Beelen, K., Hamming, L. C., Heijns, J. B., Honkoop, A. H., de Jong, P. C., van Rossum-Schornagel, Q. C., van Schaik-van de Mheen, C., Tol, J., Tromp-van Driel, C. S., Vrijaldenhoven, S., van Leeuwen-Stok, A. E., …, & Konings, I. R. (2026). Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf334
Vancouver
Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, van den Pol E, et al. Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf334
BibTeX
@article{Wortelboer2026,
author = {Wortelboer, Noor and Kent, Seamus and Blommestein, Hedwig M and van Ommen-Nijhof, Annemiek and van der Noort, Vincent and van den Pol, Esther and Páez, Cristina Guerrero and Beeker, Aart and Beelen, Karin and Hamming, Lisanne C and Heijns, Joan B and Honkoop, Aafke H and de Jong, Paul C and van Rossum-Schornagel, Quirine C and van Schaik-van de Mheen, Christa and Tol, Jolien and Tromp-van Driel, Cathrien S and Vrijaldenhoven, Suzan and van Leeuwen-Stok, A Elise and Sonke, Gabe S and Jager, Agnes and Konings, Inge R},
title = {Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf334}
}
EUVIMED